EXTON, Pa., Oct. 7, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at CPHI Worldwide in Milan, Italy to showcase leadership and expertise on industry challenges and trends in packaging and containment.
This year, West will highlight its industry expertise through a technical-focused presentation:
"The revisions to EU GMP Annex 1 represent a significant shift in drug manufacturing with over 30 references to primary packaging alone," said Cindy Reiss-Clark, Chief Commercial Officer at West. "At West, we know a drug manufacturer's contamination control strategy is only as strong as its weakest link, making the quality and control of materials from third party suppliers' critical factors to their process."
West is also a finalist for a CPHI Award in the "Heart of Pharma" category for its partnership with Fox Chase Cancer Center. This award recognizes companies, individuals and initiatives which nurture philanthropic, ethical and community-based ventures. Winners will be announced during the awards ceremony on the opening night of CPHI on October 8.
For more information about West, please visit our website: www.westpharma.com.
For more information about CPHI Worldwide, please visit: CPHI Milan
About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.
Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
| Last Trade: | US$288.66 |
| Daily Change: | -2.38 -0.82 |
| Daily Volume: | 785,604 |
| Market Cap: | US$20.940B |
April 25, 2024 February 15, 2024 December 04, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
